Tobramycin
- Generic Name
- Tobramycin
- Brand Names
- Bethkis, Kitabis, Tobi, Tobi Podhaler Weekly Kit, Tobradex, Tobrex, Zylet, Tobi Podhaler, Vantobra (previously Tobramycin PARI)
- Drug Type
- Small Molecule
- Chemical Formula
- C18H37N5O9
- CAS Number
- 32986-56-4
- Unique Ingredient Identifier
- VZ8RRZ51VK
- Background
Aminoglycosides, many of which are derived directly from Streptomyces spp., are concentration-dependent bactericidal antibiotics with a broad spectrum of activity against Gram-positive and Gram-negative organisms. Inhaled tobramycin is notable for its use in treating chronic Pseudomonas aeruginosa infections in cystic fibrosis patients, as P. aeruginosa is n...
- Indication
Inhaled tobramycin is indicated for the management of cystic fibrosis patients with Pseudomonas aeruginosa, but is not recommended in patients under six years of age, those with forced expiratory volume in 1 second (FEV) <25 or >80% predicted, or in those with Burkholderia cepacia.
...
- Associated Conditions
- Bacterial Peritonitis, Bone Infection, Cystic fibrosis, Pseudomonas aeruginosa infection, Eye Infections, Inflammation of the External Auditory Canal, Intraabdominal Infections, Lower respiratory tract infection bacterial, Meningitis, Bacterial, Ocular Inflammation, Septicemia gram-negative, Skin and Subcutaneous Tissue Bacterial Infections, Corticosteroid-responsive Disorder of the Ophthalmic, Ear infection-not otherwise specified caused by susceptible bacteria, Ocular bacterial infections, Recurrent Complicated Urinary Tract Infection, Steroid-responsive inflammation
- Associated Therapies
- -
TOBRADEX Ophthalmic Suspension Versus Tobramycin 0.3%/Dexamethasone 0.05% Ophthalmic Suspension
- Conditions
- Interventions
- First Posted Date
- 2007-12-19
- Last Posted Date
- 2010-03-02
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 221
- Registration Number
- NCT00576251
- Locations
- 🇺🇸
Houston, Houston, Texas, United States
Tobramycin Administered by eFlow Rapid Nebulizer: Pharmacokinetic Study
- Conditions
- First Posted Date
- 2007-01-11
- Last Posted Date
- 2007-01-11
- Lead Sponsor
- Novartis
- Target Recruit Count
- 20
- Registration Number
- NCT00420836
Tobramycin Inhalation Solution Administered by eFlow Rapid Nebulizer: Scintigraphy Study
- Conditions
- First Posted Date
- 2006-11-15
- Last Posted Date
- 2007-05-07
- Lead Sponsor
- Novartis
- Target Recruit Count
- 12
- Registration Number
- NCT00399945
Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Tobramycin for Bacterial Conjunctivitis (C-01-401-004)
- First Posted Date
- 2005-03-15
- Last Posted Date
- 2013-12-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 743
- Registration Number
- NCT00105469
- Locations
- 🇺🇸
Alan Shuster, MD, Jupiter, Florida, United States
🇺🇸Children's Eye Physicians, Littleton, Colorado, United States
🇺🇸Pasco Eye Institute, New Port Richey, Florida, United States
Phase III Randomized Study of the Inhalation of Tobramycin in Patients With Cystic Fibrosis
- Conditions
- First Posted Date
- 2000-02-25
- Last Posted Date
- 2015-03-25
- Lead Sponsor
- FDA Office of Orphan Products Development
- Target Recruit Count
- 200
- Registration Number
- NCT00004829
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.